Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Jessica E. Sutherland(Alnylam Pharmaceuticals (United States)), Wendell Davis(Alnylam Pharmaceuticals (United States))

Nucleic Acid Therapeutics

December 10, 2019

10.1089/nat.2019.0796

Cited by 21

Related Papers

No related papers found

Powered by citation graph analysis